Results 201 to 210 of about 136,011 (340)

Current Advances in the Combination of Fatty Acids and Resveratrol to Fight Ocular Diseases

Molecular Nutrition &Food Research, EarlyView.
Graphical abstract illustrating the effects of Resvega administration on choroidal neovascularization and resveratrol metabolism in the retina. The diagram illustrates that oral administration of Resvega leads to a decrease in choroidal neovascularization.
Dominique Delmas, Maude Perus, Virginie Aires, François Hermetet   +3 more
wiley   +1 more source

Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib

Hepatology Research, Volume 52, Issue 12, Page 1050-1059, December 2022., 2022
Abstract Aim The identification of new prognostic factors able to stratify hepatocellular carcinoma patients candidate to first‐line therapy is urgent. In the present work we validated the prognostic value of the lenvatinib prognostic index. Methods Data of Eastern and Western patients treated with lenvatinib as first‐line for Barcelona Clinic Liver ...
Margherita Rimini, Wonseok Kang, Valentina Burgio, Mara Persano, Tamoko Aoki, Shigeo Shimose, Toshifumi Tada, Takashi Kumada, Takuya Sho, Eleonora Lai, Ciro Celsa, Claudia Campani, Matteo Tonnini, Emiliano Tamburini, Atsushi Hiraoka, Koichi Takaguchi, Naoshi Nishida, Hideki Iwamoto, Ei Itobayashi, Kunihiko Tsuji, Naoya Sakamoto, Toru Ishikawa, Hidenori Toyoda, Masatoshi Kudo, Takumi Kawaguchi, Takeshi Hatanaka, Kazugiro Nouso, Goki Suda, Giuseppe Cabibbo, Fabio Marra, Angelo Della Corte, Francesca Ratti, Federica Pedica, Francesco De Cobelli, Luca Aldrighetti, Mario Scartozzi, Stefano Cascinu, Andrea Casadei‐Gardini   +37 more
wiley   +1 more source

Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies [PDF]

, 2005
Hans‐Peter Gerber, Napoleone Ferrara
openalex   +1 more source

Usefulness of neutrophil‐to‐lymphocyte ratio in predicting progression and survival outcomes after atezolizumab–bevacizumab treatment for hepatocellular carcinoma

Hepatology Research, Volume 53, Issue 1, Page 61-71, January 2023., 2023
Abstract Aim We investigated pretreatment neutrophil‐to‐lymphocyte ratio (NLR) for predicting survival outcomes of atezolizumab plus bevacizumab therapy for hepatocellular carcinoma (HCC) and determined the predictive ability of combined liver reserve–NLR.
Hironori Ochi, Masayuki Kurosaki, Kouji Joko, Toshie Mashiba, Nobuharu Tamaki, Kaoru Tsuchiya, Hiroyuki Marusawa, Toshifumi Tada, Shinichiro Nakamura, Ryoichi Narita, Yasushi Uchida, Takehiro Akahane, Masahiko Kondo, Nami Mori, Shintaro Takaki, Keiji Tsuji, Atsunori Kusakabe, Koichiro Furuta, Haruhiko Kobashi, Hirotaka Arai, Michiko Nonogi, Takashi Tamada, Chitomi Hasebe, Namiki Izumi   +23 more
wiley   +1 more source

Bleeding and thrombotic events in bevacizumab-treated patients with colorectal cancer on novel oral anticoagulants and antiplatelet medications

American Heart Journal Plus, 2023
Background: Bevacizumab is a humanized monoclonal anti-VEGF antibody often given in combination with fluorouracil-based chemotherapy as therapy for metastatic colorectal cancer (mCRC).
Shinji Rho, Chris Wang, Seyed Hamed Hosseini Dehkordi, James J. Sears, Z. Ian Hu   +4 more
doaj  

Impact of Vascular Endothelial Growth Factor-A Expression, Thrombospondin-2 Expression, and Microvessel Density on the Treatment Effect of Bevacizumab in Metastatic Colorectal Cancer [PDF]

, 2005
Adrian M. Jubb, Herbert I. Hurwitz, Wei Bai, Eric Holmgren, Patti Tobin, Angel Guerrero, Fairooz F. Kabbinavar, Scott N. Holden, William Novotny, Gretchen Frantz, Kenneth J. Hillan, Hartmut Koeppen   +11 more
openalex   +1 more source

A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Introduction Developing targeted therapies with manageable toxicities remains a high priority for pediatric cancer. We sought to determine the recommended Phase 2 dose (RP2D) and evaluate the antitumor activity of lenvatinib+everolimus in children/young adults with select recurrent/refractory solid tumors.
Filemon S. Dela Cruz, Elizabeth Fox, Steven G. DuBois, Gregory K. Friedman, James M. Croop, AeRang Kim, Daniel A. Morgenstern, Frank M. Balis, Margaret E. Macy, Joseph G. Pressey, Tanya Watt, Julie I. Krystal, Kieuhoa T. Vo, Rajen Mody, Theodore W. Laetsch, Brenda J. Weigel, Karen O'Hara, Cixin S. He, Jagadeesh Aluri, Chinyere E. Okpara, Julia L. Glade Bender   +20 more
wiley   +1 more source

Surgical Resection After Downsizing of Colorectal Liver Metastasis in the Era of Bevacizumab [PDF]

, 2005
Lee M. Ellis, Steven A. Curley, Axel Grothey   +2 more
openalex   +1 more source

Three and Four Courses of Radiation for Children with Recurrent Diffuse Intrinsic Pontine Glioma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Re‐irradiation (RT2) for children with diffuse intrinsic pontine glioma (DIPG) is increasingly used upon recurrence; however, limited data are available for evaluating additional courses of radiotherapy (RT) for DIPG. The purpose of this case series was to report our institutional experience in treating patients with recurrent DIPG ...
Nisha Shariff, Anthony Lausch, Eric Bouffet, Derek S. Tsang   +3 more
wiley   +1 more source

Molecular mechanisms of resistance to tyrosine kinase inhibitor in clear cell renal cell carcinoma

International Journal of Urology, Volume 29, Issue 12, Page 1419-1428, December 2022., 2022
Abstract Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC). Loss of von Hippel–Lindau tumor suppressor gene is frequently observed in ccRCC and increases the expression of hypoxia‐inducible factors and their targets, including epidermal growth factor, vascular endothelial growth factor, and platelet ...
Yohei Sekino, Jun Teishima, Gangning Liang, Nobuyuki Hinata   +3 more
wiley   +1 more source